Bio-Path Stock Price, News & Analysis (NASDAQ:BPTH) $0.46 0.00 (0.00%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$0.45▼$0.4750-Day Range$0.36▼$0.7552-Week Range$0.32▼$2.35Volume60,128 shsAverage Volume863,806 shsMarket Capitalization$5.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Bio-Path MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy5.63% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.62Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.67) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Bio-Path. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.63% of the outstanding shares of Bio-Path have been sold short.Short Interest Ratio / Days to CoverBio-Path has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Path has recently decreased by 28.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPTH. Previous Next 3.1 News and Social Media Coverage News SentimentBio-Path has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bio-Path this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for BPTH on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.92% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 5.74% of the stock of Bio-Path is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($1.67) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Path is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Path is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bio-Path Stock (NASDAQ:BPTH)Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.Read More BPTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPTH Stock News HeadlinesNovember 25, 2023 | americanbankingnews.comBio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.comNovember 20, 2023 | finance.yahoo.comBio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call TranscriptNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 18, 2023 | money.usnews.comBio-Path Holdings IncNovember 15, 2023 | finanznachrichten.deBio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | msn.comBio-Path GAAP EPS of -$0.32 beats by $0.02November 15, 2023 | benzinga.comBio-Path Hldgs: Q3 Earnings InsightsNovember 15, 2023 | finance.yahoo.comBio-Path Holdings Reports Third Quarter 2023 Financial ResultsNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | benzinga.comPreview: Bio-Path Holdings's EarningsNovember 8, 2023 | finance.yahoo.comBio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023October 24, 2023 | finance.yahoo.comBio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid LeukemiaOctober 13, 2023 | seekingalpha.comGRI Bio to sell 4.13M shares for holdersOctober 13, 2023 | seekingalpha.comBPTH, HARP and BTDR among mid-day moversOctober 13, 2023 | benzinga.comWhat's Going On With Bio-Path Holdings Stock?October 4, 2023 | businesswire.comDigbi Health Unveils GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1-based Personalized Care for ObesitySeptember 10, 2023 | finance.yahoo.comBio-Path Holdings, Inc.'s (NASDAQ:BPTH) Profit OutlookSeptember 8, 2023 | finance.yahoo.comBio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment ConferenceAugust 30, 2023 | finance.yahoo.comStonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23August 15, 2023 | finanznachrichten.deBio-Path Holdings, Inc.: Bio-Path Holdings Reports Second Quarter 2023 Financial ResultsAugust 15, 2023 | finance.yahoo.comBio-Path Holdings Reports Second Quarter 2023 Financial ResultsAugust 14, 2023 | benzinga.comBio-Path Holdings's Earnings OutlookAugust 8, 2023 | finance.yahoo.comBio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023August 3, 2023 | seekingalpha.comBio-Path prices 3.5M shares at $0.60 in public offeringAugust 3, 2023 | benzinga.comWhy Bio-Path Holdings (BPTH) Stock Is Down 45%August 3, 2023 | finance.yahoo.comBio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public OfferingAugust 1, 2023 | msn.comBio-Path Releases Early Cut Data From Mid-Stage Prexigebersen Trial In Acute Myeloid LeukemiaSee More Headlines Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2023Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPTH CUSIPN/A CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year Founded2007Profitability EPS (Most Recent Fiscal Year)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-216.18% Return on Assets-172.69% Debt Debt-to-Equity RatioN/A Current Ratio3.54 Quick Ratio3.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.98 per share Price / Book0.23Miscellaneous Outstanding Shares12,350,000Free Float11,992,000Market Cap$5.68 million OptionableNot Optionable Beta1.11 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Peter H. Nielsen MBA (Age 74)Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer Comp: $722.68kMr. Douglas P. Morris (Age 67)Co-Founder, Director of Investor Relations, Secretary & Director Comp: $110.68kMr. Anthony PriceSenior Vice President of Finance, Accounting & AdministrationDr. Ana Tari Ashizawa Ph.D.MBA, Senior Vice President of Research, Development & Clinical DesignKey CompetitorsSunshine BiopharmaNASDAQ:SBFMCingulateNASDAQ:CINGLixte BiotechnologyNASDAQ:LIXTPulmatrixNASDAQ:PULMCadrenal TherapeuticsNASDAQ:CVKDView All CompetitorsInstitutional OwnershipWalleye Capital LLCBought 209,238 shares on 11/21/2023Ownership: 1.694%View All Institutional Transactions BPTH Stock Analysis - Frequently Asked Questions Should I buy or sell Bio-Path stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTH shares. View BPTH analyst ratings or view top-rated stocks. How have BPTH shares performed in 2023? Bio-Path's stock was trading at $1.51 at the beginning of 2023. Since then, BPTH stock has decreased by 69.5% and is now trading at $0.4603. View the best growth stocks for 2023 here. Are investors shorting Bio-Path? Bio-Path saw a decrease in short interest in November. As of November 15th, there was short interest totaling 695,700 shares, a decrease of 28.2% from the October 31st total of 969,600 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is presently 0.3 days. View Bio-Path's Short Interest. When is Bio-Path's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our BPTH earnings forecast. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.02. During the same quarter last year, the company earned ($0.49) EPS. When did Bio-Path's stock split? Bio-Path's stock reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC). Who are Bio-Path's major shareholders? Bio-Path's stock is owned by many different retail and institutional investors. Top institutional investors include Walleye Capital LLC (1.69%). View institutional ownership trends. How do I buy shares of Bio-Path? Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BPTH) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.